Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04425421

Recommendations for the Treatment of Children With Burkitt's Lymphoma

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
French Africa Pediatric Oncology Group · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.

Detailed description

This is the 4th Burkitt's Lymphoma (LMB) study by the GFAOP group. This study hopes to include at least 14 Sub Saharian countries some of whom have never participated in a LMB study. The evaluation of improvement in early diagnosis should be possible in this study. The study hopes to be able to evaluate children earlier, with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for children with a stage IV disease. Starting from 2026 we now have the possibility of introducing rituximab into the treatment of African children with Burkitt lymphoma, starting from 15/03/2026. This amendment will prospectively evaluate the toxicity and effectiveness of adding rituximab to the current therapeutic recommendations. These results will be compared with those observed during the first years of implementation in two GFAOP units: specifically, the unit at CHU Yalgado Ouagadougou in Burkina Faso and CHU Treichville in Abidjan, Ivory Coast.

Conditions

Interventions

TypeNameDescription
OTHEROBSERVATIONALOBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE

Timeline

Start date
2020-11-01
Primary completion
2028-12-31
Completion
2030-12-31
First posted
2020-06-11
Last updated
2026-03-02

Locations

7 sites across 6 countries: Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo, Madagascar, Mali, Senegal

Source: ClinicalTrials.gov record NCT04425421. Inclusion in this directory is not an endorsement.